Krustat

Simvastatin, the active ingredient in Krustat, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adults.

GNH USA supplies Krustat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Simvastatin acts on cholesterol metabolism and is indicated for several lipid‑related conditions.

Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol levels. Primary hyperlipidemia: reduces total cholesterol, LDL and triglycerides. Prevention of cardiovascular events: decreases the risk of heart attack and stroke in patients with elevated cardiovascular risk.

Simvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Nausea - Myalgia - Constipation - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis - Elevated liver enzymes - Severe allergic reactions (e.g., rash, angioedema) - Myopathy leading to muscle weakness - Acute kidney injury - Pancreatitis

Before initiating therapy, certain safety considerations should be observed.

Liver function monitoring: assess hepatic enzymes prior to and during treatment. Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness. CYP3A4 inhibitor avoidance: avoid concomitant use with strong inhibitors that raise simvastatin levels. Pregnancy and lactation: use only if clearly needed, after risk‑benefit assessment. Renal impairment: adjust therapy based on renal function. Store at ambient temperature: keep in the original container, protect from moisture and light.

Simvastatin interacts with several medicines that can alter its plasma concentration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) - Gemfibrozil - Danazol

Moderate Interactions (Monitor Closely): - Grapefruit juice - Warfarin (may increase anticoagulant effect)